Insider Selling: Cerus (NASDAQ:CERS) COO Sells 34,094 Shares of Stock

Cerus Corporation (NASDAQ:CERS) COO Vivek Jayaraman sold 34,094 shares of Cerus stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $2.01, for a total value of $68,528.94. Following the completion of the transaction, the chief operating officer directly owned 1,912,874 shares in the company, valued at approximately $3,844,876.74. This represents a 1.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Cerus Stock Performance

Shares of CERS remained flat at $1.93 during mid-day trading on Monday. The stock had a trading volume of 2,029,960 shares, compared to its average volume of 1,640,307. Cerus Corporation has a 12 month low of $1.12 and a 12 month high of $2.96. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.73 and a quick ratio of 1.17. The firm has a market capitalization of $370.89 million, a price-to-earnings ratio of -24.13 and a beta of 1.51. The business has a 50 day moving average of $2.31 and a 200-day moving average of $1.86.

Cerus (NASDAQ:CERS) last announced its earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. The business had revenue of $64.58 million for the quarter, compared to analyst estimates of $59.31 million. Analysts expect that Cerus Corporation will post -0.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Cerus

Hedge funds have recently made changes to their positions in the company. Captrust Financial Advisors lifted its holdings in Cerus by 15.3% during the 4th quarter. Captrust Financial Advisors now owns 37,051 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 4,916 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in Cerus by 8.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 81,556 shares of the biotechnology company’s stock worth $169,000 after buying an additional 6,094 shares during the last quarter. Engineers Gate Manager LP increased its holdings in shares of Cerus by 4.7% during the fourth quarter. Engineers Gate Manager LP now owns 142,958 shares of the biotechnology company’s stock worth $294,000 after buying an additional 6,415 shares in the last quarter. Intech Investment Management LLC increased its holdings in shares of Cerus by 8.6% during the third quarter. Intech Investment Management LLC now owns 93,343 shares of the biotechnology company’s stock worth $148,000 after buying an additional 7,355 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Cerus by 68.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 18,712 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 7,603 shares during the last quarter. Institutional investors and hedge funds own 78.37% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on CERS shares. Wall Street Zen downgraded Cerus from a “buy” rating to a “hold” rating in a research report on Saturday. TD Cowen reissued a “buy” rating on shares of Cerus in a report on Monday, January 12th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold”.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.